{
  "links": "https://www.ycombinator.com/companies/biocogniv",
  "name": "Biocogniv",
  "headline": null,
  "batch": "S20",
  "description": null,
  "activity_status": "Active",
  "website": "http://biocogniv.com",
  "founded_date": 2019.0,
  "team_size": 6.0,
  "location": "Burlington, VT",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": null,
  "founders": [
    {
      "name": "Artur Adib, Founder",
      "description": "Former faculty at the National Institutes of Health (PhD in computational physics, 20+ peer-reviewed publications). Was VP Software Engineering at Beta Technologies (electric 'flying cars'), Twitter engineer (pre-IPO), and principal engineer at Magic Leap.",
      "linkedin": "https://www.linkedin.com/in/arturadib/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='News\\n[Biocogniv Achieves and Maintains ISO 13485:2016 Certification](http://biocogniv.com/</news>)\\n[![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/608189775f766b6e4644cd59_rectangle%20white%20font%20-%20transparent%20bg.png)](http://biocogniv.com/</>)\\n[](http://biocogniv.com/<#>)\\n[Home](http://biocogniv.com/</>)[News](http://biocogniv.com/</news>)[About Us](http://biocogniv.com/</about-us>)\\n[Home](http://biocogniv.com/</>)[NEWS](http://biocogniv.com/</news>)[COMPANY](http://biocogniv.com/</about-us>)\\n[Contact Us](http://biocogniv.com/</contact>)\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/613a7204d9d2d69c01085e0b_Biocogniv-Hero-09082021-BlueBackground-Narrow.png)\\nAI DIAGNOSTICS FOR ACUTE CARE\\n# Our AI sees what the eye can\\'t. Before it\\'s too late.\\nEach year, over 700,000 patients die in US hospitals, and 1 in 20 of those deaths are due to late diagnosis and intervention. We help frontline providers recognize acute conditions before they become irreversible, using state-of-the-art AI and routine tests already performed at hospitals.\\nNEWS AND PRESS RELEASES\\n### BIOCOGNIV RECEIVES BREAKTHROUGH DESIGNATION FROM FDA\\n[More News](http://biocogniv.com/</news>)\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/614b8869474b3eb8f0893b97_rack.jpg)\\nour innovation engine\\n## AI-based predictive diagnostics\\nThe confluence of large clinical databases and high-performance artificial intelligence (AI) models is enabling a new paradigm in medical diagnostics.\\u200dBiocogniv has built proprietary platforms and datasets that power real world evidence of unprecedented scale, allowing us to discover new opportunities without incurring the risk and high cost of traditional clinical trials.Our first product, Sepsis aiMarker™, can detect and predict sepsis up to 72 hours in advance using only routine laboratory panels collected in the emergency room, and has been granted a Breakthrough Designation by FDA.\\n##### 16 Million+\\n###### PATIENT ENCOUNTERS\\n##### 1 Billion+\\n###### LAB RESULTS\\nSELECT PARTNERS\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a21603013aa55770c4d29_UTMB_Health_PMS_rev300DPI.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/612fd4faf6d78c07f0dbf18f_sjgh.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a24e48255e45acaeffce0_vituity.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606cdfa06ddcbff2fa4b157a_nih-logo.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/61d9dd374175665472eea46f_nsf.png)\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/614b934aa788e200de591e60_frank.png)\\nTESTIMONIAL\\n\"Having worked on novel biomarkers for decades, I am genuinely impressed and excited about Biocogniv’s ability to leverage routine blood tests to detect acute conditions before they become obvious. **Biocogniv\\'s AI-based biomarkers could soon become part of the standard of care in emergency medicine**.\"\\n## W. Frank Peacock, MD FACEP FACC\\n## Thought leader in acute care biomarkersVice Chair, Emergency Medicine ResearchBaylor College of Medicine\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/613157bf726645828f191026_josh.png)\\nTESTIMONIAL\\n\"I oversee innovation at an organization that employs 5,000 frontline providers at hundreds of hospitals, so we\\'ve seen many products. I believe **Biocogniv\\'s** **AI biomarkers are a breakthrough in medicine** as they go beyond traditional alerts that merely point out what can be known without them – it identifies what is not clinically evident, as early as possible in the patient trajectory.\"\\n## Joshua Tamayo-Sarver, MD PhD FACEP\\n## **Vice President of Innovation, VituityEmergency Physician and BiostatisticianGood Samaritan Hospital, CA**\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a2980f6487852f24b3f8a_peter.png)\\nTESTIMONIAL\\n\"We have worked on a blinded, independent validation of Biocogniv\\'s digital biomarker, using a large dataset from our 1,000-bed system. **The accuracy of the predictions were in excellent agreement with the expected performance** of the tool. I think this is going to change how acute conditions are approached by providers.\"\\n## Peter McCaffrey, MD FCAP\\n## Director, Lab Information ServicesDirector, Pathology InformaticsUniversity of Texas Medical Branch (UTMB)\\n![logo](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/608189e5e388e59cad8156ff_rectangle%20dark%20font%20-%20transparent%20bg.png)\\n**Address:** 50 Lakeside Ave.Suite 851Burlington, VT 05401United States**Email:** contact@biocogniv.com**Phone:** +1 (802) 222-6973\\nLinks\\n[News](http://biocogniv.com/</news>)[About Us](http://biocogniv.com/</about-us>)[Contact](http://biocogniv.com/</contact>)\\nCopyright ©2024 Biocogniv Inc. All rights reserved.\\n[![](https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d6f91252fd62f3d9d233139_twitter%20\\\\(4\\\\).svg)](http://biocogniv.com/<https:/twitter.com/madebyflowcraft>)[![](https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d6f91252fd62f9df7233138_instagram%20\\\\(6\\\\).svg)](http://biocogniv.com/<https:/www.instagram.com/madebyflowcraft/>)[![](https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d81e9e6e7908e56bf587612_Gumroad.svg)](http://biocogniv.com/<https:/gumroad.com/flowcraft>)\\n[![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/6063dd32263478927ce60356_chevron_arrow.svg)](http://biocogniv.com/<#Navigation>)\\n' markdown_with_citations='News\\nBiocogniv Achieves and Maintains ISO 13485:2016 Certification⟨1⟩\\n![⟨2⟩](http://biocogniv.com/</>)\\n[](http://biocogniv.com/<#>)\\nHome⟨3⟩News⟨1⟩About Us⟨4⟩\\nHome⟨3⟩NEWS⟨1⟩COMPANY⟨4⟩\\nContact Us⟨5⟩\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/613a7204d9d2d69c01085e0b_Biocogniv-Hero-09082021-BlueBackground-Narrow.png)\\nAI DIAGNOSTICS FOR ACUTE CARE\\n# Our AI sees what the eye can\\'t. Before it\\'s too late.\\nEach year, over 700,000 patients die in US hospitals, and 1 in 20 of those deaths are due to late diagnosis and intervention. We help frontline providers recognize acute conditions before they become irreversible, using state-of-the-art AI and routine tests already performed at hospitals.\\nNEWS AND PRESS RELEASES\\n### BIOCOGNIV RECEIVES BREAKTHROUGH DESIGNATION FROM FDA\\nMore News⟨1⟩\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/614b8869474b3eb8f0893b97_rack.jpg)\\nour innovation engine\\n## AI-based predictive diagnostics\\nThe confluence of large clinical databases and high-performance artificial intelligence (AI) models is enabling a new paradigm in medical diagnostics.\\u200dBiocogniv has built proprietary platforms and datasets that power real world evidence of unprecedented scale, allowing us to discover new opportunities without incurring the risk and high cost of traditional clinical trials.Our first product, Sepsis aiMarker™, can detect and predict sepsis up to 72 hours in advance using only routine laboratory panels collected in the emergency room, and has been granted a Breakthrough Designation by FDA.\\n##### 16 Million+\\n###### PATIENT ENCOUNTERS\\n##### 1 Billion+\\n###### LAB RESULTS\\nSELECT PARTNERS\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a21603013aa55770c4d29_UTMB_Health_PMS_rev300DPI.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/612fd4faf6d78c07f0dbf18f_sjgh.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a24e48255e45acaeffce0_vituity.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606cdfa06ddcbff2fa4b157a_nih-logo.png)![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/61d9dd374175665472eea46f_nsf.png)\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/614b934aa788e200de591e60_frank.png)\\nTESTIMONIAL\\n\"Having worked on novel biomarkers for decades, I am genuinely impressed and excited about Biocogniv’s ability to leverage routine blood tests to detect acute conditions before they become obvious. **Biocogniv\\'s AI-based biomarkers could soon become part of the standard of care in emergency medicine**.\"\\n## W. Frank Peacock, MD FACEP FACC\\n## Thought leader in acute care biomarkersVice Chair, Emergency Medicine ResearchBaylor College of Medicine\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/613157bf726645828f191026_josh.png)\\nTESTIMONIAL\\n\"I oversee innovation at an organization that employs 5,000 frontline providers at hundreds of hospitals, so we\\'ve seen many products. I believe **Biocogniv\\'s** **AI biomarkers are a breakthrough in medicine** as they go beyond traditional alerts that merely point out what can be known without them – it identifies what is not clinically evident, as early as possible in the patient trajectory.\"\\n## Joshua Tamayo-Sarver, MD PhD FACEP\\n## **Vice President of Innovation, VituityEmergency Physician and BiostatisticianGood Samaritan Hospital, CA**\\n![](https://cdn.prod.website-files.com/6063dd32263478400ee6030e/606a2980f6487852f24b3f8a_peter.png)\\nTESTIMONIAL\\n\"We have worked on a blinded, independent validation of Biocogniv\\'s digital biomarker, using a large dataset from our 1,000-bed system. **The accuracy of the predictions were in excellent agreement with the expected performance** of the tool. I think this is going to change how acute conditions are approached by providers.\"\\n## Peter McCaffrey, MD FCAP\\n## Director, Lab Information ServicesDirector, Pathology InformaticsUniversity of Texas Medical Branch (UTMB)\\n![logo⟨6⟩]\\n**Address:** 50 Lakeside Ave.Suite 851Burlington, VT 05401United States**Email:** contact@biocogniv.com**Phone:** +1 (802) 222-6973\\nLinks\\nNews⟨1⟩About Us⟨4⟩Contact⟨5⟩\\nCopyright ©2024 Biocogniv Inc. All rights reserved.\\n![⟨7⟩.svg)](http://biocogniv.com/<https:/twitter.com/madebyflowcraft>)![⟨8⟩.svg)](http://biocogniv.com/<https:/www.instagram.com/madebyflowcraft/>)![⟨9⟩](http://biocogniv.com/<https:/gumroad.com/flowcraft>)\\n![⟨10⟩](http://biocogniv.com/<#Navigation>)\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ http://biocogniv.com/</news>: Biocogniv Achieves and Maintains ISO 13485:2016 Certification\\n⟨2⟩ https://cdn.prod.website-files.com/6063dd32263478400ee6030e/608189775f766b6e4644cd59_rectangle%20white%20font%20-%20transparent%20bg.png: ![\\n⟨3⟩ http://biocogniv.com/</>: Home\\n⟨4⟩ http://biocogniv.com/</about-us>: About Us\\n⟨5⟩ http://biocogniv.com/</contact>: Contact Us\\n⟨6⟩ https://cdn.prod.website-files.com/6063dd32263478400ee6030e/608189e5e388e59cad8156ff_rectangle%20dark%20font%20-%20transparent%20bg.png: logo\\n⟨7⟩ https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d6f91252fd62f3d9d233139_twitter%20\\\\(4\\\\: ![\\n⟨8⟩ https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d6f91252fd62f9df7233138_instagram%20\\\\(6\\\\: ![\\n⟨9⟩ https://cdn.prod.website-files.com/5d6f91252fd62f03bd2330e7/5d81e9e6e7908e56bf587612_Gumroad.svg: ![\\n⟨10⟩ https://cdn.prod.website-files.com/6063dd32263478400ee6030e/6063dd32263478927ce60356_chevron_arrow.svg: ![\\n' fit_markdown='' fit_html=''",
  "generated_description": "**Biocogniv: Pioneering AI Diagnostics in Acute Care**\n\nFounded in 2019 and hailing from Burlington, Vermont, Biocogniv is an emerging player in the healthcare technology space. The company advanced through Y Combinator's Summer 2020 batch, and it operates with a lean, dedicated team of six employees.\n\n**Mission and Vision**\n\nBiocogniv's mission revolves around utilizing advanced artificial intelligence to enhance diagnostic capabilities, particularly in acute conditions. Each year, late diagnoses account for a staggering 700,000 patient deaths in U.S. hospitals; Biocogniv is tackling this issue head-on. Their innovative approach aims to help frontline healthcare providers recognize critical conditions before they escalate, thereby saving lives.\n\n**AI-Driven Solutions**\n\nAt the core of Biocogniv's offerings is their flagship product, Sepsis aiMarker™. This groundbreaking tool employs AI to predict sepsis up to 72 hours in advance using routine lab tests conducted in emergency settings. Recently, Biocogniv earned the FDA's Breakthrough Device designation for this product, underscoring its potential to transform acute care.\n\n**Proven Impact**\n\nBiocogniv is leveraging vast clinical databases and sophisticated AI algorithms to develop unprecedented real-world evidence. With over 16 million patient encounters and more than a billion lab results analyzed, the company is positioned to lead the next evolution in medical diagnostics, reducing reliance on costly clinical trials.\n\n**Accolades and Partnerships**\n\nThe company has achieved notable milestones, including maintaining ISO 13485:2016 certification, which is pivotal for companies involved in medical device manufacturing. Moreover, Biocogniv's efforts have been validated by leading figures in emergency medicine, evidencing their credibility in the industry. Testimonials highlight how the AI-based biomarkers developed by Biocogniv are on track to become integral to standard care in emergency departments.\n\n**Contact and Further Information**\n\nFor those interested in learning more about Biocogniv and its innovative solutions in AI diagnostics, you can visit [Biocogniv's website](http://biocogniv.com). The company is located at 50 Lakeside Ave., Suite 851, Burlington, VT 05401, and can be reached at +1 (802) 222-6973 or via email at contact@biocogniv.com.\n\nIn summary, Biocogniv is poised to revolutionize the acute care landscape by harnessing the power of AI to improve early diagnosis and treatment. Their commitment to innovation reflects a promising shift in how healthcare meets urgent patient needs."
}